Selenium supplementation and insulin resistance in a randomized, clinical trial
| Autor: | Nathan A. Ellis, Janet A. Foote, H-H. Sherry Chow, Jessica A. Martinez, Patricia A. Thompson, Ken Batai, Peter Lance, Elizabeth T. Jacobs, Lawrence J. Mandarino, Chiu-Hsieh Paul Hsu, Kathylynn Saboda |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adenoma
Adult Male homeostatic model assessment medicine.medical_specialty Endocrinology Diabetes and Metabolism medicine.medical_treatment 030209 endocrinology & metabolism Type 2 diabetes Placebo Gastroenterology law.invention 03 medical and health sciences Selenium 0302 clinical medicine Insulin resistance Polyps Randomized controlled trial law Diabetes mellitus Internal medicine Insulin-Secreting Cells insulin resistance medicine HOMA OGTT Humans Epidemiology/Health Services Research Aged Randomized Controlled Trials as Topic Aged 80 and over business.industry Insulin Middle Aged medicine.disease 3. Good health Clinical trial 030220 oncology & carcinogenesis Dietary Supplements supplementation Homeostatic model assessment Female business Colorectal Neoplasms |
| Zdroj: | BMJ Open Diabetes Research & Care |
| ISSN: | 2052-4897 |
| Popis: | ObjectiveWhile controversial, observational and randomized clinical trial data implicate the micronutrient selenium (Se) in the development of type 2 diabetes (T2D). The aim of this study was to test the hypothesis that Se supplementation adversely affects pancreatic β-cell function and insulin sensitivity.Research design and methodsIn a subset of 400 individuals participating in a randomized, placebo-controlled trial of Se at 200 µg/day for colorectal adenomatous polyps, fasting plasma glucose and insulin were measured before randomization and within 6 months of completing intervention. Change in the homeostasis model assessment-β cell function (HOMA2-%β) and insulin sensitivity (HOMA2-%S) were compared between arms. A subgroup of 175 (79 Se and 96 placebo) participants underwent a modified oral glucose tolerance test (mOGTT) at the end of intervention and change in glucose values was assessed.ResultsNo statistically significant differences were observed for changes in HOMA2-%β or HOMA2-%S between those who received Se compared with placebo. After a mean of 2.9 years on study, mean HOMA2-%β values were 3.1±24.0 and 3.1±29.8 for the Se and placebo groups, respectively (p=0.99). For HOMA2-%S, the values were −0.5±223.2 and 80.9±1530.9 for the Se and placebo groups, respectively (p=1.00). Stratification by sex or age did not reveal any statistically significant effects on insulin sensitivity by treatment group. For mOGTT, mean baseline fasting blood glucose concentrations were significantly higher among participants in the placebo group compared with the Se group (96.6±14.6 and 92.3±12.0, respectively; p=0.04), a trend which remained through the 20 min assessment.ConclusionsThese findings do not support a significant adverse effect of daily Se supplementation with 200 µg/day of selenized yeast on β-cell function or insulin sensitivity as an explanation for previously reported associations between Se and T2D. Further clarification of longer term effects of Se is needed.Clinical trial registryNIH Clinical Trials.gov numberNCT00078897. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|